Summary & Overview
HCPCS J0833: Cosyntropin Injection, 0.25 mg
HCPCS Level II code J0833 designates a 0.25 mg injection of cosyntropin, an ACTH analog used in diagnostic stimulation testing and select therapeutic contexts. Nationally, accurate coding for injectable agents affects billing consistency, payer coverage determination, and clinical documentation for endocrine testing and inpatient/outpatient care.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical purpose and usual settings for J0833, plus coverage and billing considerations across major national payers. The publication outlines common service lines and sites where cosyntropin injections are billed, typical documentation elements needed to support medical necessity, and how J0833 interacts with related administration and supply reporting.
The analysis also highlights benchmarking points useful for revenue cycle and compliance teams, and synthesizes policy updates relevant to injectable diagnostic agents. This summary is intended for coding professionals, clinical billing staff, and policy analysts seeking an actionable primer on HCPCS Level II code J0833 and its role in endocrine testing workflows and injectable medication billing.
Billing Code Overview
HCPCS Level II code J0833 represents injection, cosyntropin, not otherwise specified, 0.25 mg. The service is an injectable diagnostic or therapeutic medication administration involving a 0.25 mg dose of cosyntropin supplied for injection. The typical site of service for this injectable medication is outpatient clinic, hospital outpatient department, or physician office where parenteral medications and diagnostic stimulation tests are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45–70-year-old adult referred to an outpatient infusion clinic or hospital outpatient department for diagnostic adrenal axis testing. The provider administers J0833 (cosyntropin 0.25 mg) intramuscularly or intravenously to evaluate adrenal insufficiency when the patient presents with unexplained fatigue, weight loss, orthostatic hypotension, hyponatremia, or hypoglycemia. The clinical workflow includes review of history and medications (for example, recent glucocorticoid use), baseline vital signs and serum cortisol/ACTH sampling, administration of J0833, and timed post-injection cortisol measurements (typically at 30 and 60 minutes) to assess adrenal responsiveness. Observation for adverse reactions occurs on site for at least 30–60 minutes; results guide endocrinology diagnosis and further management, such as pituitary imaging or glucocorticoid replacement if tests indicate insufficiency.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable E/M service by the same physician on the same day | Use when a separate evaluation and management visit is provided the same day as J0833. |
| Professional component | Use when billing separate professional component for interpretation if applicable (rare for injectable diagnostic agents).